Stanford V, is a chemotherapy regimen intended as a first-line treatment for Hodgkin lymphoma. The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as ABVD. The chemical agents used are:A mustard derivative such as cyclophosphamide, chlormethine or ifosfamide Doxorubicin, an anti-tumor antibiotic Vinblastine, an alkaloid cell toxin Vincristine, another alkaloid cell toxin Bleomycin, another anti-tumor antibiotic Etoposide, a DNA toxin Prednisone, a corticosteroid